Lausanne, Switzerland And Mechelen, Belgium (ots/PRNewswire) - Today Biocartis and VIB announced their exclusive license agreement on a novel panel of microsatellite instability (MSI) biomarkers for several cancers, in particular colorectal cancer (CRC). This agreement will enable Biocartis to develop a unique and user-friendly assay, whereby MSI biomarkers can simply ...
Mechelen, Belgium And Lausanne, Switzerland (ots/PRNewswire) - Biocartis, a molecular diagnostics company developing and commercializing innovative, easy to use platforms and clinically relevant assays, announced today the completion of an EUR 30 million Series E equity fundraising. The additional capital will be ...
Mechelen, Belgium And Lausanne, Switzerland (ots/PRNewswire) - Biocartis also introduces IdyllaTM, the brand name for its innovative and high-quality diagnostic platform (previously codenamed Apollo). IdyllaTM is designed to carry out fast and accurate analysis of a broad range of clinical samples[1]. The platform ...
Lausanne, Switzerland, Mechelen, Belgium And Barcelona, Spain (ots/PRNewswire) - Today Biocartis and Hospital del Mar announced their licence agreement on the EGFR biomarker for colon cancer. This agreement enables Biocartis to develop a new colon cancer test, whereby a specific EGFR mutation can be rapidly and ...
Lausanne, Switzerland And Mechelen, Belgium (ots/PRNewswire) - Biocartis, a molecular diagnostics company, announces today that Ulrik Cordes has joined the company as Chief Commercial Officer (CCO). Ulrik Cordes is an executive with 18+ years of experience in marketing and sales in the med-tech, pharma and biotech industry, of which the past 10 years in top level management roles. "We are delightedtowelcomeUlrik to ...
Lausanne, Switzerland And Mechelen, Belgium (ots/PRNewswire) - Biocartis, a molecular diagnostics company developing and commercializing innovative, high quality, easy to use platforms and clinically relevant oncology assays, announced today that Inge Basteleurs has joined the company as General Counsel. Inge will be a member of Biocartis' Executive Committee and a ...
Lausanne, Switzerland (ots/PRNewswire) - - Capital to be used to commercialize recently launched DMAT platform, validate APOLLO platform and build proprietary oncology content on both platforms - Strong support from internal shareholders and a recognition of our achievements Biocartis, a molecular diagnostics company developing and commercializing innovative, high ...
Lausanne, Switzerland (ots/PRNewswire) - Biocartis launches its revolutionary detection platform, Dynamic Multi-Analyte Technology ("DMAT"): - New proteomic and nucleic acid platform provides ultra-high quality data analysis even at higher multiplex formats. - Platform launched well ahead of plan. Biocartis flips from a late-stage development company into a commercial ...